Tripep AB (publ) AGM 2003

The Annual General Meeting of Tripep AB The Annual General Meeting of Tripep AB was held in Stockholm on 27 March, 2003. The Company's income statement and balance sheet were adopted and the Board of Directors and the Managing Director were discharged from liability for the fiscal year 2002. All Directors of the Board were re-elected, i.e. Rolf L Nordström, Anders Vahlne, Matti Sällberg and Erik Nerpin. Anders Wiger, Ernst & Young was re-elected auditor of the Company. Marine Gesien, Ernst & Young, was elected deputy auditor. The Meeting resolved, in accordance with the Board of Director's proposal, to re-purchase the Company's own shares. The repurchase will be carried out through an offer to all shareholders to sell one share for SEK 30 in cash for each ten shares held. The record date for receiving sale rights is 8 April 2003. Each share carries one sales right and ten sale rights carry entitlement to sell one share during the period 15 April - 6 May 2003. The Meeting resolved, in accordance with the Board of Directors' proposal, to implement an option program. The Company shall issue a maximum of 750,000 promissory notes with detachable warrants. Each warrant entitles the holder to subscribe for a new share in the Company during the period 7 October 2005 - 7 April 2006. Entitled to subscribe for the promissory notes with detachable warrants shall be the members of the Company's Scientific Advisory Board, the Board member Matti Sällberg, the Managing Director, other employees and the Company's consultants. The Board of Directors withdrew the proposal for an authorization for the Board of Directors to resolve a new issue of shares. The Meeting resolved to establish a nomination committee consisting of the Chairman of the Board Rolf L Nordström, Peter Horal and Bo Svennerholm. The Meeting resolved not to instruct the Board of Directors to establish an audit committee and a compensation committee. At the Statutory meeting of the Board of Directors subsequent to the Meeting, Rolf L Nordström was re-elected Chairman of the Board. For more information, please contact: Johan Ihre, President Tel.: +46 8-449 84 80, mobile tel.: +46 707-33 44 25 e-mait: johan.ihre@tripep.se or Anders Vahlne, VP, Head of Research Tel.: +46 8-5858 1313, mobile tel.: +46 709-28 05 28 e-mail: anders.vahlne@impi.ki.se Web site: www.tripep.se ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/03/28/20030328BIT00100/wkr0001.doc http://www.waymaker.net/bitonline/2003/03/28/20030328BIT00100/wkr0002.pdf

About Us

ChronTech has developed and further develops a patent pending new type of injection needle for a more effective uptake of genetic vaccines (IVIN) and vaccine and therapy for hepatitis D. ChronTech also have part ownership in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se.

Subscribe